Why You Should Be Wary Of Target-Date Funds It's the

New Post Public Reply Private Reply Replies (0) Message Board
NITE

Why You Should Be Wary Of Target-Date Funds

It's the "in thing" now; everybody's doing it, so why wouldn't you? Here's how the story repeatedly plays out, especially for those who recently opened a new 401(k) or 403(b) account. The benefits manager of your company sent you a big stack of documents and told you to complete the application. You thumbed through everything, skimming the microscopic print in these pamphlets called prospectuses, and found yourself completely overwhelmed.

Luckily, as you were completing the application, you noticed that you could either pick your own investment options or choose the ready-made option that placed all of your retirement funds into a target-date fund. You didn't know what it was, but you didn't know how to pick your investment options anyway, so into this target-date fund is where your money has gone.



What Is a Target-Date Fund?
The concept is very simple. A target-date fund adjusts the assets in the fund to line up with your retirement timeline. If you're planning to retire in 15 years, you might pick a target-date fund of 2025 or 2030. The fund manager will adjust the holdings and when you near retirement age, that fund will hold a lot of bonds, instead of the more risky stocks.

You don't have to worry about adjusting your investment portfolio because the fund does it for you. If you don't have the time or desire to learn how to manage your retirement portfolio, these target-date funds might be a great idea.

As your grandparents might have said, if it's too good to be true, it probably isn't and that might be the case with target-date funds.

The Whole You
First, you are more than a date. Knowing that you plan to retire in 2025 or 2030 isn't enough information to assemble your retirement portfolio; imagine a doctor asking nothing more than your age. Your investment portfolio should be crafted around your tolerance for risk, the other assets you own, your family situation, social security and more. A target-date fund doesn't take any of that into account, because it's designed for a large amount instead of you, personally.

They Might Cost a Lot
According to Consumer Reports, the median expense ratio of target-date funds is 0.68%, compared to 0.71% for stock funds. That isn't bad if your plan offers a target-date fund around the median, but the median expense ratio of index funds, a fund that tracks the performance of a certain investment index, is only 0.5% and you can find index funds for as low as 0.1%.

In general, actively managed funds, funds that have a team of people picking stocks and bonds in an attempt to beat the overall market, will cost more, but over the long term they don't perform any better than an index fund that is cheaper.

They're Hard to Understand
Target-date funds are like a brand new car . They look good on the outside but they're hard to figure out when you open the hood. A recent SEC study found that many people believed that a target-date fund guarantees an income stream at retirement much like an annuity or a pension.

Others believed that once the fund reached the target-date, no more allocation changes in the fund were made. Both of these facts are untrue but this, along with the fact that a 2025 fund may vary greatly between companies, makes these funds dangerous for investors to take at face value.
The Bottom Line
Regardless of what you read today or in the future, there is no one investment product that will address all of your investing needs. A combination of products that may include a target-date fund is the best way to insure your retirement needs are met. Diversification will likely always be the best way to protect and grow your portfolio.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

XMax's $30M Repurchase: Strategic Value Move

Updated Category News Views 57

XMax Enters Share Repurchase Game Who doesn’t love a buyback announcement from a company trying to put some faith back in its stock? XMax Inc., a name juggling the dual act of AI innovation and contemporary furniture dealings, just dropped a $30 million share repurchase bombshell. The firm aims to scoop up shares priced under $5.50, signifying it might think the...

Continue Reading
HikTech Star Tour Highlights Co-Innovation at Hikvision

Updated Category News Views 73

Innovation Meets Collaboration at HikTech Star Tour Ever been to one of those tech expos that's more about hype than substance? No smoke and mirrors here. The 2026 HikTech Star Tour wasn’t your run-of-the-mill tech meet-up. Held in Hangzhou, the event brought together 130 tech professionals from 56 countries. It’s like a digital United Nations, but with fewer speeches...

Continue Reading
New CEO at Armor: Nicholas Lee Takes Helm

Updated Category News Views 75

Leadership Shakeup at Armor Well, here's a twist in the ever-spinning merry-go-round of tech leadership: Armor's got a new top dog. Nicholas Lee, the former big shot at Fujitsu Intelligence, is now steering the ship as CEO, effective November 2, 2026. With his broad and varied playbook in tech and AI, Lee's stepping into some big shoes with plans to bolster Armor’s...

Continue Reading
Gutiérrez Honored with Enrique V. Iglesias Award

Updated Category News Views 85

Gutiérrez Recognized for Civic and Business Impact Alright, folks, here's a scenario to chew on: Dionisio Gutiérrez, a name that's likely resonated in business and civic corridors for a while, is about to add another feather to his cap. This November 4, Gutiérrez will bask in the limelight as King Felipe VI of Spain hands him the 11th Enrique V. Iglesias Award. It's...

Continue Reading
MIAX Preps New Binary Options Amid SEC Filings

Updated Category News Views 50

MIAX's Strategic Move Towards Binary Options Ah, that's something that might just shake things up a bit. On November 3rd, 2026, MIAMI International Holdings (NYSE: MIAX) made the headlines by filing with the SEC to offer cash-settled binary index options. Now, if you're not new to the trading game, you know that anything involving SEC registration gets the blood pumping....

Continue Reading
Hidden Fences: A Smarter Choice for Pet Owners?

Updated Category News Views 14

The Case for Invisible Fences Man's best friend meets modern containment! Why are hidden fences gaining traction in households across Culpeper, VA, and beyond? Pet Containment Expert Lawrence Sowers spills some valuable insights into why so many are ditching traditional fences. Practical reasons abound, folks! Keeping the Yard Beautiful Who wants their landscaping ruined...

Continue Reading
Q-Ball Intelligence Launches Predictive Powerhouse

Updated Category News Views 22

Breaking Out in the Predictive AI Scene Q-Ball Intelligence doesn't just stroll onto the AI stage; they bulldoze in, backed by a beefy research legacy starting way back in 2007. Now, after 19 years marinating in the depths of predictive research—and putting some serious cash where their AI mouth is—they've officially launched as the new big thing in predictive...

Continue Reading
TETRA Hits High Mark with Robust Q3 Earnings Surge

Updated Category News Views 118

Financial Milestones and Market Insights Boy, if you're not watching TETRA Technologies (NYSE:TTI) right now, you're probably missing out on a real barnstormer of a financial report. The numbers are looking chalkboards-be-damned stellar! They’ve just notched their finest third quarter in a decade, bringing in revenues through the roof at $168 million—an impressive 10%...

Continue Reading
Summit Midstream Prepares for Q3 2026 Earnings Report

Updated Category News Views 96

Quarterly financials are the canary in the coal mine for any energy firm. Scrutinizing those numbers can be the difference between riding a bull market or nursing your wounds in a ditch. So, what's on tap for Summit Midstream Corporation (NYSE: SMC)? They've circled November 9, 2026, on the calendar for releasing their third quarter figures, just after the NYSE bell...

Continue Reading
Boston Scientific's SIMPLAAFY Trial Promises Post-Op Ease

Updated Category News Views 160

SIMPLAAFY Trial Makes Waves in Cardiac Care Alright, let's dig into the heart of the matter—pun fully intended. Boston Scientific (NYSE:BSX) just rolled out some head-turning results from their SIMPLAAFY study, which evaluates the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device. What’s so special, you ask? Well, it’s all about simplifying the post-surgery...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Church & Dwight Co's Upcoming Earnings Trends

Updated Category News Views 260

A Deep Dive into Church & Dwight Co's Earnings Potential Church & Dwight Co (NYSE: CHD) is gearing up to reveal its quarterly earnings report. Investors are keenly awaiting insights that could impact the company's future outlook and stock performance. Analysts forecast an earnings per share (EPS) of $0.73, but many are hoping for even better results. Understanding Past...

Continue Reading
Aimco to Release Q3 2024 Earnings Results Soon

Updated Category News Views 197

Aimco to Announce Third Quarter Earnings Apartment Investment and Management Company, commonly known as Aimco (NYSE: AIV), is preparing to share its financial performance for the third quarter of 2024. The company will issue its earnings report after market closure on the scheduled date. This announcement marks a significant moment for investors and analysts watching...

Continue Reading
October 2025 Transport Statistics of AS Tallink Grupp

Updated Category News Views 133

Insights from AS Tallink Grupp's October Performance In October 2025, AS Tallink Grupp reported transporting 467,279 passengers, marking a notable 2.5% decline from October 2024. Alongside this, the volume of cargo units saw a significant downturn, decreasing by 10.2%, totaling 21,855 units. Additionally, passenger vehicles also dipped, with a reduction of 2.6%, bringing...

Continue Reading
Eupraxia Pharmaceuticals Shares Exciting Updates on EoE Trial

Updated Category News Views 287

Eupraxia Pharmaceuticals' Latest Trial Results for EP-104GI Eupraxia Pharmaceuticals Inc. (TSX: EPRX) has reported exciting news regarding its ongoing clinical trial for the treatment of eosinophilic esophagitis (EoE) with EP-104GI. This treatment aims to alleviate symptoms and improve the quality of life for patients suffering from this challenging condition. Highlights...

Continue Reading
Clarius Named in TIME's Top HealthTech 2026 Again

Updated Category News Views 31

When a company gets the nod from TIME two years in a row, you know they’re not just tinkering with gadgets—they’re changing the game. Clarius Mobile Health, with its cutting-edge wireless ultrasound tech, has cemented its place in TIME's World's Top HealthTech Companies of 2026. Last I checked, repeating this kind of recognition never comes easy in such a fiercely...

Continue Reading